Within hours, the world will have a better idea about the prospects of a new Alzheimer's treatment when Japanese drugmaker Eisai releases late-stage clinical trial results.
The big picture: News of a second patient death linked to the drug has dampened expectations and potentially created a more complicated path for the drug hitting the market.
